Sagent Pharma launched Ceftazidime for injection USP
Sagent Pharma today announced that it has launched Ceftazidime for injection USP, a semisynthetic broad-spectrum, beta-lactam antibiotic. Sagent will offer ceftazidime in 1 and 2g single dose vials and 6g pharmacy bulk package vials. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $45.7 million.
Sagent’s ceftazidime is the generic equivalent of GlaxoSmithKline’s FORTAZ®.
Ranbaxy Lab announced launch of Amlodipine tablets
Ranbaxy Lab announced launch of Amlodipine tablets 2.5mg & 5mg in Japan . Amlodipine is currently the largest molecule which has gone off patent in Japan and represents the biggest generic opportunity so far in the Japanese generic market. The product has a market size of around USD 2 Billion.
No comments:
Post a Comment